Delving into the Latest Updates on Viventia Biotech, Inc. with Synapse

Overview

Tags

Neoplasms

Biological products

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6

Top 5 Drug Type	Count

Biological products	5
Monoclonal antibody	1

Top 5 Target	Count

CD44 x EpCAM	2
HER2(Receptor tyrosine-protein kinase erbB-2)	1
CD44(CD44 antigen)	1
SLC2A8(solute carrier family 2 member 8)	1

A RANDOMIZED, MULTICENTRE THERAPEUTIC CONFIRMATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROXINIUM™ PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE RECEIVED AT LEAST ONE ANTI-CANCER TREATMENT REGIMEN FOR ADVANCED DISEASE

Start Date19 Apr 2007

Sponsor / Collaborator

Viventia Biotech, Inc.

100 Clinical Results associated with Viventia Biotech, Inc.

Login to view more data

0 Patents (Medical) associated with Viventia Biotech, Inc.

Login to view more data

19

Literatures (Medical) associated with Viventia Biotech, Inc.

01 Sep 2009·Medical OncologyQ4 · MEDICINE

A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck

Q4 · MEDICINE

Article

Author: M. Kowalski ; W. Cuthbert ; M. Rasamoelisolo ; N. Glover ; J. Entwistle ; Maureen A. Spearman ; G. C. MacDonald

VB4-845 is a novel recombinant fusion protein that targets the epithelial cellular adhesion molecule (EpCAM). This initial clinical trial was conducted to determine the maximum tolerated dose of intratumoral injections in patients with advanced squamous cell carcinoma of the head and neck and to assess pharmacokinetics and immunogenicity. Twenty-four patients with advanced, recurrent squamous cell carcinoma of the head and neck received two cycles of five daily intratumoral VB4-845 injections of 20, 40, 80, 130, 200, or 280 microg. The maximum tolerated dose was established to be 280 microg administered daily for 5 days. Common adverse events were pain due to intratumoral injection and reversibly elevated liver enzymes. Of the 24 patients, 15 had detectable blood levels with a mean drug half-life of 4.0 +/- 0.3 h. VB4-845 reduced or stabilized tumors in 71.4% of epithelial cell adhesion molecule-positive patients. VB4-845 intratumoral injection therapy was well tolerated and feasible.

01 Sep 2006·Biochemical and Biophysical Research CommunicationsQ3 · BIOLOGY

A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab™ PF-2D in tandem with mass spectrometry

Q3 · BIOLOGY

Article

Author: Joycelyn Entwistle ; Francina C. Chahal ; Nick Glover ; Glen C. MacDonald

Mapping differential expression of soluble proteins has become fairly routine using chromatofocusing in combination with the reversed-phase HPLC (ProteomeLab PF-2D by Beckman Coulter Inc.); however, identification of membrane antigens has not been reported thus far. In this report, we demonstrate a targeted proteomic approach employing immunoprecipitation, prior to 2D-LC separation, in tandem with MS/MS that can be used to identify tumor-associated membrane antigens. This system is very sensitive and reproducible in that only 1/4th the amount of starting material is required for analysis as compared to gel-based analysis, and permits a focused environment for eliminating non-specific interactions leading to an accurate resolution of the cognate antigen. This system also circumvents the well-known limitations associated with gel-based approaches. This approach has been validated in the identification of ErB2/HER-2 and was subsequently used to identify CD44E as the cognate antigen for VB1-008, one of our fully human, tumor-specific, monoclonal antibodies.

01 Mar 2005·Current opinion in drug discovery & development

Effective tumor targeting: strategies for the delivery of Armed Antibodies.

Review

Author: MacDonald, Glen C ; Glover, Nick

It has long been realized that the presence of tumor-associated antigens offers an excellent opportunity for targeted cancer therapy and hence an improved clinical benefit for cancer patients. Advances in the field of antibody engineering as well as the characterization of toxins, such as diphtheria toxin and Pseudomonas exotoxin A, have enabled the routine construction of recombinant immunotoxins, which we have termed Armed Antibodies. The selective toxicity and mechanism of action of these molecules could potentially provide an excellent clinical alternative to conventional anticancer agents which have many unacceptable side effects. Although considerable clinical success has been achieved using immunotoxin therapy, particularly for B-cell malignancies, the treatment of solid tumors remains highly challenging. To successfully treat solid tumors that are not amenable to local therapy, immunotoxins must be designed to permit repeat systemic administration. This review outlines some of the strategies currently being employed in the design of the Viventia Biotech Inc Armed Antibodies to minimize the development of immunogenicity and to remove the potential for toxicity in non-target tissues.

100 Deals associated with Viventia Biotech, Inc.

Login to view more data

100 Translational Medicine associated with Viventia Biotech, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

6

9

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

VB1-050(Viventia Biotech) ( SLC2A8 )	Neoplasms More	Preclinical
VB-6008(Viventia Biotech, Inc.) ( CD44 )	Neoplasms More	Preclinical
VB-7756(Viventia Biotech, Inc.) ( HER2 )	Neoplasms More	Preclinical
VB-6901(Viventia Biotech, Inc.) ( CD44 x EpCAM )	Neoplasms More	Preclinical
VB-6050(Viventia Biotech, Inc.) ( CD44 x EpCAM )	Neoplasms More	Preclinical